4.6 Article

Investigating Effects of Proteasome Inhibitor on Multiple Myeloma Cells Using Confocal Raman Microscopy

Journal

SENSORS
Volume 16, Issue 12, Pages -

Publisher

MDPI AG
DOI: 10.3390/s16122133

Keywords

Raman spectroscopy; Raman microscopy; therapeutic response monitoring; cell imaging

Funding

  1. NIH [P41-EB015871-30]
  2. Samsung Advanced Institute of Technology (Seoul, South Korea)
  3. Singapore-MIT Alliance 2 (Cambridge, MA, USA)
  4. Biosym IRG of Singapore-MIT Alliance Research and Technology Center (Cambridge, MA, USA)
  5. Hamamatsu Corporation (Hamamatsu City, Japan)
  6. [U01-NS090438-03]
  7. [R21-NS091982-01]
  8. [R01-HL121386-03]

Ask authors/readers for more resources

Due to its label-free and non-destructive nature, applications of Raman spectroscopic imaging in monitoring therapeutic responses at the cellular level are growing. We have recently developed a high-speed confocal Raman microscopy system to image living biological specimens with high spatial resolution and sensitivity. In the present study, we have applied this system to monitor the effects of Bortezomib, a proteasome inhibitor drug, on multiple myeloma cells. Cluster imaging followed by spectral profiling suggest major differences in the nuclear and cytoplasmic contents of cells due to drug treatment that can be monitored with Raman spectroscopy. Spectra were also acquired from group of cells and feasibility of discrimination among treated and untreated cells using principal component analysis (PCA) was accessed. Findings support the feasibility of Raman technologies as an alternate, novel method for monitoring live cell dynamics with minimal external perturbation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available